AtaiBeckley Inc. Common Stock (ATAI) Stock Price

ATAIStock

$7.44+61.49%52W

Market Cap$2.76B

P/E—

PEG Ratio—

Div yield—

Beta1.59

ATAI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)75.59%

Price vs S&P 500 (4W)-0.27%

VGM Score46.93

Book Value / Share (Quarterly)$0.54

P/TBV (Annual)6.78x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)160.99%

Cash Flow / Share (Quarterly)$-0.31

Price vs S&P 500 (YTD)68.48%

Net Profit Margin (TTM)-19019.44%

EPS (TTM)$-2.23

10-Day Avg Trading Volume7.08M

EPS Excl Extra (TTM)$-2.23

EPS (Annual)$-2.91

ROI (Annual)-297.49%

Net Profit Margin (5Y Avg)-28899.22%

Cash / Share (Quarterly)$0.63

Revenue Growth QoQ (YoY)-38.65%

ROA (Last FY)-225.49%

Revenue Growth TTM (YoY)86.72%

EBITD / Share (TTM)$-2.38

ROE (5Y Avg)-109.07%

Operating Margin (TTM)-18569.09%

Cash Flow / Share (Annual)$-0.31

P/B Ratio13.53x

P/B Ratio (Quarterly)6.50x

Net Income / Employee (Annual)$-6,667,100

EV / Revenue (TTM)758.51x

Net Interest Coverage (TTM)-40.12x

ROA (TTM)-268.96%

EPS Incl Extra (Annual)$-2.91

Current Ratio (Annual)11.74x

Quick Ratio (Quarterly)9.90x

3-Month Avg Trading Volume10.55M

52-Week Price Return61.49%

Revenue / Employee (TTM)$35,200

Tangible BV / Share (Quarterly)$0.54

P/S Ratio (Annual)657.56x

Asset Turnover (Annual)0.01x

52-Week High$7.45

Operating Margin (5Y Avg)-29988.13%

EPS Excl Extra (Annual)$-2.91

CapEx CAGR (5Y)182.88%

26-Week Price Return86.84%

Quick Ratio (Annual)11.56x

13-Week Price Return70.44%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.02x

Enterprise Value$2.65B

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$41,300

Pretax Margin (Annual)-16137.17%

Cash / Share (Annual)$0.70

3-Month Return Std Dev92.40%

Net Income / Employee (TTM)$-6,701,000

ROE (Last FY)-297.49%

Net Interest Coverage (Annual)-88.98x

EPS Basic Excl Extra (Annual)$-2.91

Receivables Turnover (TTM)0.05x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.23

Receivables Turnover (Annual)0.03x

ROI (TTM)-363.40%

P/S Ratio (TTM)770.86x

Pretax Margin (5Y Avg)-27255.25%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$0.60

Price vs S&P 500 (52W)43.18%

Year-to-Date Return80.44%

5-Day Price Return1.23%

EPS Normalized (Annual)$-2.91

ROA (5Y Avg)-84.65%

Net Profit Margin (Annual)-16142.02%

Month-to-Date Return2.79%

Cash Flow / Share (TTM)$-0.41

EBITD / Share (Annual)$-2.81

Operating Margin (Annual)-15582.27%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-103.88%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.23

P/TBV (Quarterly)6.59x

P/B Ratio (Annual)6.70x

Pretax Margin (TTM)-19017.26%

Book Value / Share (Annual)$0.61

Price vs S&P 500 (13W)67.64%

Beta1.59x

Revenue / Share (TTM)$0.01

ROE (TTM)-366.49%

52-Week Low$3.27

vGradeF

gGradeC

mGradeA

vgmGradeC

ATAI Earnings Surprise History

Q2 25-0.14est. -0.12

Q3 25-0.28est. -0.12

Q4 25-1.73est. -0.11

Q2 26-0.09est. -0.11

ATAI Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.20

4.24

3.57

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ATAIAtaiBeckley Inc. Common Stock	F	C	A	$7.44
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About AtaiBeckley Inc. Common Stock

AtaiBeckley Inc is a clinical-stage biopharmaceutical company developing novel therapies for psychiatric disorders, with a focus on rapid-acting and convenient treatment options. The company's Phase 2 pipeline includes three candidates: BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, VLS-01 (DMT buccal film) for treatment-resistant depression and social anxiety disorder, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. These programs address significant unmet medical needs in mental health treatment.